Brain Amyloidosis Is Associated with Worse Cognitive Performance in Both the Cognitively Normal and Impaired Stages – a [18f]Flutemetamol PET Study

Trial Profile

Brain Amyloidosis Is Associated with Worse Cognitive Performance in Both the Cognitively Normal and Impaired Stages – a [18f]Flutemetamol PET Study

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Flutemetamol-F-18 (Primary)
  • Indications Dementia
  • Focus Diagnostic use
  • Most Recent Events

    • 19 Oct 2015 New trial record
    • 23 Jul 2015 Results presented at the 2015 Alzheimer's Association International Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top